DIABETES Breaking news! Rosiglitazone and cardiovascular risk

被引：10

作者：

Kaul, Sanjay ^{[1
]}

Diamond, George A. ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA

来源：

NATURE REVIEWS CARDIOLOGY | 2010年 / 7卷 / 12期

关键词：

MYOCARDIAL-INFARCTION; HEART-FAILURE; DEATH;

D O I：

10.1038/nrcardio.2010.160

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the past 3 years, several studies have reignited the controversy regarding the cardiovascular risk associated with the use of rosiglitazone. Until a prospective, well-controlled, randomized clinical trial is performed to adjudicate the issue definitively, physicians should be free to exercise clinical judgment, and weigh the comparative risks and benefits of agents such as rosiglitazone on a case-by-case basis.

引用

页码：670 / 672

页数：4

共 10 条

[1] A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure [J].

Dargie, Henry J. ;

Hildebrandt, Per R. ;

Riegger, Guenter A. J. ;

McMurray, John J. V. ;

McMorn, Stephen O. ;

Roberts, Jeremy N. ;

Zambanini, Andrew ;

Wilding, John P. H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (16) :1696-1704

[2] Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death [J].

Diamond, George A. ;

Bax, Leon ;

Kaul, Sanjay .

ANNALS OF INTERNAL MEDICINE, 2007, 147 (08) :578-581

[3]

*FDA, 2009, FDA ADDS BOX WARN HE

[4]

FDA, 2007, JOINT M END MET DRUG

[5] Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data [J].

Friedrich, Jan O. ;

Adhikari, Neill K. J. ;

Beyene, Joseph .

BMC MEDICAL RESEARCH METHODOLOGY, 2007, 7 (1)

[6] Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone [J].

Graham, David J. ;

Ouellet-Hellstrom, Rita ;

MaCurdy, Thomas E. ;

Ali, Farzana ;

Sholley, Christopher ;

Worrall, Christopher ;

Kelman, Jeffrey A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (04) :411-418

[7] Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function [J].

McGuire, Darren K. ;

Abdullah, Shuaib M. ;

See, Raphael ;

Snell, Peter G. ;

McGavock, Jonathan ;

Szczepaniak, Lidia S. ;

Ayers, Colby R. ;

Drazner, Mark H. ;

Khera, Amit ;

de Lemos, James A. .

EUROPEAN HEART JOURNAL, 2010, 31 (18) :2262-2270

[8] Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].

Nissen, Steven E. ;

Wolski, Kathy .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471

[9] Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality [J].

Nissen, Steven E. ;

Wolski, Kathy .

ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (14) :1191-1201

[10] Simpson's paradox visualized:: The example of the Rosiglitazone meta-analysis [J].

Ruecker, Gerta ;

Schumacher, Martin .

BMC MEDICAL RESEARCH METHODOLOGY, 2008, 8 (1)

← 1 →